Exhaled nitric oxide and atherosclerosis
- 15 February 2012
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 42 (8) , 873-880
Abstract
Eur J Clin Invest 2012 Abstract Background Fractional exhaled nitric oxide concentration (FENO) measurement has been proposed to be an important adjunct in the diagnosis and management of asthma, pulmonary hypertension and cystic fibrosis. But do we understand how other diseases influence the FENO values? In particular, atherosclerosis is one of the pathological conditions, in which nitric oxide (NO) production is inhibited and its degradation enhanced. Therefore, hypothesis of the current study was that FENO is inversely associated with risk markers of atherosclerosis and with diseases leading secondarily to the progression of atherosclerosis. Materials and methods A long-term FENO value (median of biweekly measurements over a 24-week period) of 53 patients with ischaemic heart disease (IHD) was compared with the results of clinical and biochemical analyses. Results Fractional exhaled NO was inversely associated with the plasma concentration of triglycerides (P = 0·01) and with the blood concentration of glycated haemoglobin A1c (P = 0·03). It also tended to be inversely associated with the plasma glucose concentration (P = 0·10). However, there were no statistically significant associations with inflammatory or other biochemical markers, health status, lifestyle or other personal determinants. Conclusions In accordance with the hypothesis, FENO is inversely associated with some of risk markers of atherosclerosis in patients with stable IHD (triglycerides and haemoglobin A1c, a marker of hyperglycaemic metabolism). A potential explanation is that, at hyperglycaemia and with higher triglyceride concentrations, atherosclerosis leads to endothelial dysfunction and, subsequently, to decreased production and increased degradation of NO.Keywords
This publication has 20 references indexed in Scilit:
- Retinal Arteriolar Tortuosity and Cardiovascular Risk Factors in a Multi-Ethnic Population Study of 10-Year-Old Children; the Child Heart and Health Study in England (CHASE)Arteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Exhaled Nitric Oxide in Pulmonary DiseasesChest, 2010
- Association between exhaled nitric oxide and systemic inflammatory markersAnnals of Allergy, Asthma & Immunology, 2007
- Air Pollution and Inflammation (Interleukin-6, C-Reactive Protein, Fibrinogen) in Myocardial Infarction SurvivorsEnvironmental Health Perspectives, 2007
- Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart FailureCirculation, 2005
- C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery diseaseEuropean Heart Journal, 2004
- Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbitsJACC, 1996
- Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.Journal of Clinical Investigation, 1995
- Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells.Journal of Clinical Investigation, 1989